18F-mFBG Imaging for Neural Crest Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter. In addition to collecting safety data for the imaging agent, the study aims to:* compare the findings against other catacholamine transporters* evaluate the imaging results at different time points and in different organs* assess the quality of images with lower doses* compare the ability to detect neuroblastoma lesions against other imaging agents, and in other tumors
Who Is on the Research Team?
Alice Lee, MD
Principal Investigator
Montefiore Medical Center/Albert Einstein College of Medicine
Are You a Good Fit for This Trial?
This trial is for individuals with neuroblastoma, paraganglioma, or pheochromocytoma. It's designed to see how well a new imaging agent called 18F-mFBG shows these tumors and organs affected by the sympathetic nervous system on PET scans.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Tissue Sampling
Participants undergo 18F-mFBG PET imaging and tissue sampling for NET expression analysis
Follow-up
Participants are monitored for safety and effectiveness after imaging and tissue sampling
What Are the Treatments Tested in This Trial?
Interventions
- 18F-mFBG
Find a Clinic Near You
Who Is Running the Clinical Trial?
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Lead Sponsor
Albert Einstein College of Medicine
Collaborator